- Efficacy and Safety of Chimeric Antigen Receptor T Cells Therapy Strategy with Dual Targeting of CD19 and CD70 to Treat Relapsed/Refractory Diffuse Large B-Cell LymphomaTu, Sanfang; Zhou, Lijuan; Huang, Rui; Zhou, Xuan; Yang, Jilong; Li, Meifang; Jin, Bo; Wang, Langqi; Zhuo, Yaqi; Chen, Huifang; Chang, Lung-Ji; Li, Yuhua65th Annual Meeting of the American-Society-of-Hematology (ASH), San Diego, CA, 2023-12-09 To 2023-12-12.
- Efficacy and Safety of Interleukin-6-Knockdown CD19-Targeted CAR T Cells(ssCART-19) for Relapsed/Refractory B-ALLKang, Liqing; Ma, Jinfeng; Lou, Xiaoyan; Tang, Xiaowen; Xue, Shengli; Chen, Suning; Qiu, Huiying; Miao, Miao; Han, Yue; Wang, Ying; Sun, Aining; Dai, Haiping; Xu, Yang; Li, Limin; Fan, Shengjin; Qian, Chongsheng; Gong, Wenjie; Xu, Mingzhu; Zhou, Haixia; Yao, Zhen65th Annual Meeting of the American-Society-of-Hematology (ASH), San Diego, CA, 2023-12-09 To 2023-12-12.
- Efficacy and Safety of Chimeric Antigen Receptor T Cells Therapy Combined with Zanubrutinib in the Treatment of Relapsed/Refractory Diffuse Large B-Cell LymphomaWang, Langqi; Yang, Jilong; Jin, Bo; Wang, Bo; Zhou, Lijuan; Zhuo, Yaqi; Chen, Huifang; Chang, Lung-Ji; Tu, Sanfang; Li, Yuhua65th Annual Meeting of the American-Society-of-Hematology (ASH), San Diego, CA, 2023-12-09 To 2023-12-12.
会议论文
Efficacy and Safety of Chimeric Antigen Receptor T Cells Therapy Strategy That Dual Targeting CD19 and CD22 to Treat Relapsed/Refractory Acute Lymphoblastic Leukemia in Adults
19阅读
